Related references
Note: Only part of the references are listed.Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
Andries M. Bergman et al.
INVESTIGATIONAL NEW DRUGS (2011)
Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells
A. D. Adema et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2010)
Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study
Svein Dueland et al.
ACTA ONCOLOGICA (2009)
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines
Carlos M. Galmarini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Innovations and Opportunities to Improve Conventional (Deoxy) Nucleoside and Fluoropyrimidine Analogs in Cancer
A. D. Adema et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Systemic chemotherapy for advanced non-small cell lung cancer: Recent advances and future directions
Suresh Ramalingam et al.
ONCOLOGIST (2008)
The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry
R. Honeywell et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines
AM Bergman et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts
AM Bergman et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2004)
The systemic treatment of advanced and metastatic bladder cancer
SA Hussain et al.
LANCET ONCOLOGY (2003)
Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials
V Heinemann
SEMINARS IN ONCOLOGY (2002)
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
AM Bergman et al.
DRUG RESISTANCE UPDATES (2002)